600
Participants
Start Date
July 20, 2024
Primary Completion Date
June 23, 2025
Study Completion Date
May 31, 2027
Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis
"1. Subcutaneous Allergen-Specific Immunotherapy:~ * Pre-treatment: Omalizumab subcutaneous injection, with the total IgE level serving as the basis for calculating the dosage for children. The appropriate dosage of omalizumab (each dose ranging from 75 to 600 mg) and administration frequency (once every 4 weeks) are determined based on the baseline IgE (IU/mL, measured before the start of treatment) and body weight (kg).~ * Mite Allergen Preparation: (Antergen/Alutard)~2. Standard Treatment:~ * Asthma: Inhaled corticosteroids (ICS) combined with long-acting beta-2 agonists, leukotriene receptor antagonists.~ * Allergic Rhinitis: Oral antihistamines, nasal antihistamines, nasal corticosteroids, anti-leukotriene drugs, cromolyn sodium, decongestants (oxymetazoline hydrochloride), and nasal saline irrigation."
RECRUITING
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai
Wenjing Zhou
OTHER